Fluorine in PDB 5vp1: Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders
Enzymatic activity of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders
All present enzymatic activity of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders:
3.1.4.17;
Protein crystallography data
The structure of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders, PDB code: 5vp1
was solved by
I.D.Hoffman,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Resolution Low / High (Å)
|
30.00 /
1.86
|
Space group
|
C 1 2 1
|
Cell size a, b, c (Å), α, β, γ (°)
|
165.129,
72.712,
90.061,
90.00,
109.15,
90.00
|
R / Rfree (%)
|
22.5 /
24.3
|
Other elements in 5vp1:
The structure of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders also contains other interesting chemical elements:
Fluorine Binding Sites:
The binding sites of Fluorine atom in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders
(pdb code 5vp1). This binding sites where shown within
5.0 Angstroms radius around Fluorine atom.
In total 9 binding sites of Fluorine where determined in the
Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders, PDB code: 5vp1:
Jump to Fluorine binding site number:
1;
2;
3;
4;
5;
6;
7;
8;
9;
Fluorine binding site 1 out
of 9 in 5vp1
Go back to
Fluorine Binding Sites List in 5vp1
Fluorine binding site 1 out
of 9 in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 1 of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F1004
b:31.0
occ:1.00
|
F28
|
A:9GA1004
|
0.0
|
31.0
|
1.0
|
C27
|
A:9GA1004
|
1.4
|
29.6
|
1.0
|
F30
|
A:9GA1004
|
2.2
|
30.3
|
1.0
|
F29
|
A:9GA1004
|
2.3
|
31.1
|
1.0
|
O26
|
A:9GA1004
|
2.3
|
28.3
|
1.0
|
C25
|
A:9GA1004
|
2.9
|
25.9
|
1.0
|
C24
|
A:9GA1004
|
3.0
|
25.5
|
1.0
|
CG2
|
A:ILE866
|
3.3
|
26.9
|
1.0
|
CD1
|
A:ILE870
|
3.4
|
26.1
|
1.0
|
CD1
|
A:LEU770
|
3.6
|
24.5
|
1.0
|
CD1
|
A:LEU809
|
3.6
|
22.2
|
1.0
|
C31
|
A:9GA1004
|
4.1
|
24.2
|
1.0
|
CD2
|
A:HIS773
|
4.2
|
24.9
|
1.0
|
C23
|
A:9GA1004
|
4.2
|
24.3
|
1.0
|
CG
|
A:LEU809
|
4.3
|
21.7
|
1.0
|
CG
|
A:HIS773
|
4.5
|
24.2
|
1.0
|
CD2
|
A:LEU809
|
4.6
|
21.4
|
1.0
|
CB
|
A:THR805
|
4.7
|
21.9
|
1.0
|
CG
|
A:LEU770
|
4.7
|
24.9
|
1.0
|
CB
|
A:LEU770
|
4.8
|
23.4
|
1.0
|
CB
|
A:HIS773
|
4.8
|
23.6
|
1.0
|
NE2
|
A:HIS773
|
4.8
|
25.9
|
1.0
|
CB
|
A:ILE866
|
4.8
|
28.2
|
1.0
|
CA
|
A:LEU770
|
4.8
|
22.9
|
1.0
|
CG2
|
A:THR805
|
4.8
|
22.2
|
1.0
|
CG1
|
A:ILE870
|
4.9
|
26.5
|
1.0
|
|
Fluorine binding site 2 out
of 9 in 5vp1
Go back to
Fluorine Binding Sites List in 5vp1
Fluorine binding site 2 out
of 9 in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 2 of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F1004
b:31.1
occ:1.00
|
F29
|
A:9GA1004
|
0.0
|
31.1
|
1.0
|
C27
|
A:9GA1004
|
1.4
|
29.6
|
1.0
|
O26
|
A:9GA1004
|
2.3
|
28.3
|
1.0
|
F28
|
A:9GA1004
|
2.3
|
31.0
|
1.0
|
F30
|
A:9GA1004
|
2.3
|
30.3
|
1.0
|
CB
|
A:HIS773
|
3.1
|
23.6
|
1.0
|
CG2
|
A:THR805
|
3.1
|
22.2
|
1.0
|
CG
|
A:HIS773
|
3.3
|
24.2
|
1.0
|
C25
|
A:9GA1004
|
3.5
|
25.9
|
1.0
|
CB
|
A:THR805
|
3.6
|
21.9
|
1.0
|
CD2
|
A:HIS773
|
3.7
|
24.9
|
1.0
|
ND1
|
A:HIS773
|
4.0
|
25.0
|
1.0
|
CA
|
A:LEU770
|
4.1
|
22.9
|
1.0
|
CD1
|
A:LEU770
|
4.1
|
24.5
|
1.0
|
CD1
|
A:ILE870
|
4.2
|
26.1
|
1.0
|
C24
|
A:9GA1004
|
4.3
|
25.5
|
1.0
|
C31
|
A:9GA1004
|
4.4
|
24.2
|
1.0
|
O
|
A:ALA767
|
4.4
|
23.3
|
1.0
|
OG1
|
A:THR805
|
4.5
|
22.5
|
1.0
|
CA
|
A:HIS773
|
4.5
|
23.7
|
1.0
|
NE2
|
A:HIS773
|
4.5
|
25.9
|
1.0
|
O
|
A:ASP769
|
4.5
|
22.3
|
1.0
|
N
|
A:LEU770
|
4.6
|
22.5
|
1.0
|
CE1
|
A:HIS773
|
4.7
|
25.6
|
1.0
|
CB
|
A:LEU770
|
4.7
|
23.4
|
1.0
|
CA
|
A:THR805
|
4.8
|
21.8
|
1.0
|
C
|
A:ASP769
|
4.8
|
22.3
|
1.0
|
O
|
A:LEU770
|
4.8
|
23.5
|
1.0
|
O
|
A:HOH1134
|
4.9
|
22.0
|
1.0
|
C
|
A:LEU770
|
5.0
|
23.1
|
1.0
|
N
|
A:HIS773
|
5.0
|
23.2
|
1.0
|
O
|
A:THR768
|
5.0
|
21.9
|
1.0
|
O
|
A:HOH1182
|
5.0
|
22.4
|
1.0
|
|
Fluorine binding site 3 out
of 9 in 5vp1
Go back to
Fluorine Binding Sites List in 5vp1
Fluorine binding site 3 out
of 9 in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 3 of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F1004
b:30.3
occ:1.00
|
F30
|
A:9GA1004
|
0.0
|
30.3
|
1.0
|
C27
|
A:9GA1004
|
1.4
|
29.6
|
1.0
|
F28
|
A:9GA1004
|
2.2
|
31.0
|
1.0
|
O26
|
A:9GA1004
|
2.3
|
28.3
|
1.0
|
F29
|
A:9GA1004
|
2.3
|
31.1
|
1.0
|
C25
|
A:9GA1004
|
2.8
|
25.9
|
1.0
|
C31
|
A:9GA1004
|
3.2
|
24.2
|
1.0
|
CB
|
A:THR805
|
3.2
|
21.9
|
1.0
|
CG2
|
A:THR805
|
3.4
|
22.2
|
1.0
|
C24
|
A:9GA1004
|
3.7
|
25.5
|
1.0
|
CA
|
A:THR805
|
3.7
|
21.8
|
1.0
|
CG
|
A:LEU809
|
3.7
|
21.7
|
1.0
|
CD1
|
A:LEU809
|
3.8
|
22.2
|
1.0
|
O
|
A:THR805
|
3.9
|
23.2
|
1.0
|
CD1
|
A:ILE870
|
4.1
|
26.1
|
1.0
|
CD2
|
A:LEU809
|
4.1
|
21.4
|
1.0
|
C
|
A:THR805
|
4.2
|
22.4
|
1.0
|
C32
|
A:9GA1004
|
4.3
|
23.6
|
1.0
|
OG1
|
A:THR805
|
4.4
|
22.5
|
1.0
|
CB
|
A:ASP808
|
4.5
|
20.3
|
1.0
|
C23
|
A:9GA1004
|
4.7
|
24.3
|
1.0
|
OD2
|
A:ASP808
|
4.8
|
20.8
|
1.0
|
C22
|
A:9GA1004
|
4.9
|
23.2
|
1.0
|
O
|
A:THR768
|
5.0
|
21.9
|
1.0
|
|
Fluorine binding site 4 out
of 9 in 5vp1
Go back to
Fluorine Binding Sites List in 5vp1
Fluorine binding site 4 out
of 9 in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 4 of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
B:F1003
b:31.2
occ:1.00
|
F28
|
B:9GA1003
|
0.0
|
31.2
|
1.0
|
C27
|
B:9GA1003
|
1.4
|
29.5
|
1.0
|
F29
|
B:9GA1003
|
2.2
|
31.1
|
1.0
|
F30
|
B:9GA1003
|
2.3
|
30.1
|
1.0
|
O26
|
B:9GA1003
|
2.3
|
28.5
|
1.0
|
C25
|
B:9GA1003
|
2.9
|
26.2
|
1.0
|
C24
|
B:9GA1003
|
3.1
|
26.4
|
1.0
|
CG2
|
B:ILE866
|
3.2
|
29.9
|
1.0
|
CD1
|
B:ILE870
|
3.4
|
29.0
|
1.0
|
CD1
|
B:LEU770
|
3.6
|
28.2
|
1.0
|
CD1
|
B:LEU809
|
3.6
|
24.9
|
1.0
|
CG2
|
B:THR805
|
3.9
|
31.1
|
1.0
|
C31
|
B:9GA1003
|
4.0
|
25.3
|
1.0
|
CD2
|
B:HIS773
|
4.2
|
28.5
|
1.0
|
C23
|
B:9GA1003
|
4.3
|
25.1
|
1.0
|
CG
|
B:LEU809
|
4.4
|
24.2
|
1.0
|
CG
|
B:HIS773
|
4.5
|
28.1
|
1.0
|
CD2
|
B:LEU809
|
4.6
|
23.7
|
1.0
|
CB
|
B:ILE866
|
4.7
|
30.4
|
1.0
|
CG
|
B:LEU770
|
4.7
|
28.4
|
1.0
|
NE2
|
B:HIS773
|
4.8
|
28.8
|
1.0
|
CB
|
B:HIS773
|
4.8
|
28.1
|
1.0
|
CB
|
B:LEU770
|
4.8
|
27.3
|
1.0
|
CG1
|
B:ILE870
|
4.8
|
29.5
|
1.0
|
CA
|
B:LEU770
|
4.8
|
27.1
|
1.0
|
C32
|
B:9GA1003
|
5.0
|
23.7
|
1.0
|
|
Fluorine binding site 5 out
of 9 in 5vp1
Go back to
Fluorine Binding Sites List in 5vp1
Fluorine binding site 5 out
of 9 in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 5 of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
B:F1003
b:31.1
occ:1.00
|
F29
|
B:9GA1003
|
0.0
|
31.1
|
1.0
|
C27
|
B:9GA1003
|
1.4
|
29.5
|
1.0
|
O26
|
B:9GA1003
|
2.2
|
28.5
|
1.0
|
F28
|
B:9GA1003
|
2.2
|
31.2
|
1.0
|
F30
|
B:9GA1003
|
2.3
|
30.1
|
1.0
|
CB
|
B:HIS773
|
3.0
|
28.1
|
1.0
|
CG
|
B:HIS773
|
3.3
|
28.1
|
1.0
|
CG2
|
B:THR805
|
3.3
|
31.1
|
1.0
|
OG1
|
B:THR805
|
3.4
|
30.7
|
1.0
|
C25
|
B:9GA1003
|
3.5
|
26.2
|
1.0
|
CD2
|
B:HIS773
|
3.7
|
28.5
|
1.0
|
CA
|
B:LEU770
|
4.0
|
27.1
|
1.0
|
CB
|
B:THR805
|
4.0
|
28.8
|
1.0
|
ND1
|
B:HIS773
|
4.0
|
28.3
|
1.0
|
CD1
|
B:LEU770
|
4.0
|
28.2
|
1.0
|
CD1
|
B:ILE870
|
4.2
|
29.0
|
1.0
|
C24
|
B:9GA1003
|
4.3
|
26.4
|
1.0
|
C31
|
B:9GA1003
|
4.3
|
25.3
|
1.0
|
O
|
B:ALA767
|
4.5
|
24.9
|
1.0
|
O
|
B:ASP769
|
4.5
|
27.0
|
1.0
|
N
|
B:LEU770
|
4.5
|
26.7
|
1.0
|
NE2
|
B:HIS773
|
4.5
|
28.8
|
1.0
|
CA
|
B:HIS773
|
4.5
|
29.0
|
1.0
|
CB
|
B:LEU770
|
4.7
|
27.3
|
1.0
|
CE1
|
B:HIS773
|
4.7
|
28.9
|
1.0
|
C
|
B:ASP769
|
4.7
|
26.5
|
1.0
|
O
|
B:LEU770
|
4.8
|
28.5
|
1.0
|
C
|
B:LEU770
|
4.9
|
27.8
|
1.0
|
O
|
B:HOH1144
|
4.9
|
23.3
|
1.0
|
CA
|
B:THR805
|
4.9
|
26.4
|
1.0
|
O
|
B:THR768
|
4.9
|
24.6
|
1.0
|
N
|
B:HIS773
|
5.0
|
28.4
|
1.0
|
CG
|
B:LEU770
|
5.0
|
28.4
|
1.0
|
|
Fluorine binding site 6 out
of 9 in 5vp1
Go back to
Fluorine Binding Sites List in 5vp1
Fluorine binding site 6 out
of 9 in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 6 of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
B:F1003
b:30.1
occ:1.00
|
F30
|
B:9GA1003
|
0.0
|
30.1
|
1.0
|
C27
|
B:9GA1003
|
1.4
|
29.5
|
1.0
|
O26
|
B:9GA1003
|
2.2
|
28.5
|
1.0
|
F28
|
B:9GA1003
|
2.3
|
31.2
|
1.0
|
F29
|
B:9GA1003
|
2.3
|
31.1
|
1.0
|
C25
|
B:9GA1003
|
2.7
|
26.2
|
1.0
|
CG2
|
B:THR805
|
2.9
|
31.1
|
1.0
|
C31
|
B:9GA1003
|
3.1
|
25.3
|
1.0
|
OG1
|
B:THR805
|
3.6
|
30.7
|
1.0
|
CB
|
B:THR805
|
3.6
|
28.8
|
1.0
|
C24
|
B:9GA1003
|
3.7
|
26.4
|
1.0
|
CD1
|
B:LEU809
|
3.8
|
24.9
|
1.0
|
CG
|
B:LEU809
|
3.8
|
24.2
|
1.0
|
CA
|
B:THR805
|
3.8
|
26.4
|
1.0
|
O
|
B:THR805
|
3.9
|
25.3
|
1.0
|
CD1
|
B:ILE870
|
4.1
|
29.0
|
1.0
|
CD2
|
B:LEU809
|
4.2
|
23.7
|
1.0
|
C32
|
B:9GA1003
|
4.2
|
23.7
|
1.0
|
C
|
B:THR805
|
4.3
|
25.6
|
1.0
|
CB
|
B:ASP808
|
4.5
|
22.0
|
1.0
|
C23
|
B:9GA1003
|
4.7
|
25.1
|
1.0
|
OD2
|
B:ASP808
|
4.7
|
22.6
|
1.0
|
O
|
B:THR768
|
4.9
|
24.6
|
1.0
|
C22
|
B:9GA1003
|
4.9
|
24.4
|
1.0
|
|
Fluorine binding site 7 out
of 9 in 5vp1
Go back to
Fluorine Binding Sites List in 5vp1
Fluorine binding site 7 out
of 9 in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 7 of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
C:F1003
b:31.6
occ:1.00
|
F28
|
C:9GA1003
|
0.0
|
31.6
|
1.0
|
C27
|
C:9GA1003
|
1.4
|
30.6
|
1.0
|
F30
|
C:9GA1003
|
2.3
|
31.7
|
1.0
|
F29
|
C:9GA1003
|
2.3
|
30.1
|
1.0
|
O26
|
C:9GA1003
|
2.3
|
29.7
|
1.0
|
C25
|
C:9GA1003
|
2.9
|
27.2
|
1.0
|
C24
|
C:9GA1003
|
3.1
|
27.3
|
1.0
|
CG2
|
C:ILE866
|
3.2
|
29.9
|
1.0
|
CD1
|
C:ILE870
|
3.4
|
27.1
|
1.0
|
CD1
|
C:LEU809
|
3.6
|
23.1
|
1.0
|
CD1
|
C:LEU770
|
3.6
|
29.5
|
1.0
|
C31
|
C:9GA1003
|
4.0
|
25.6
|
1.0
|
CD2
|
C:HIS773
|
4.2
|
31.6
|
1.0
|
C23
|
C:9GA1003
|
4.3
|
26.7
|
1.0
|
CG
|
C:LEU809
|
4.4
|
22.1
|
1.0
|
CG
|
C:HIS773
|
4.5
|
30.4
|
1.0
|
CD2
|
C:LEU809
|
4.6
|
22.3
|
1.0
|
CB
|
C:ILE866
|
4.7
|
30.8
|
1.0
|
CB
|
C:THR805
|
4.7
|
22.4
|
1.0
|
CG
|
C:LEU770
|
4.8
|
29.5
|
1.0
|
NE2
|
C:HIS773
|
4.8
|
32.4
|
1.0
|
CB
|
C:HIS773
|
4.8
|
29.4
|
1.0
|
CB
|
C:LEU770
|
4.8
|
28.2
|
1.0
|
CG1
|
C:ILE870
|
4.8
|
27.3
|
1.0
|
CA
|
C:LEU770
|
4.9
|
27.7
|
1.0
|
CG2
|
C:THR805
|
4.9
|
22.3
|
1.0
|
O
|
C:ILE866
|
5.0
|
29.7
|
1.0
|
C32
|
C:9GA1003
|
5.0
|
24.9
|
1.0
|
|
Fluorine binding site 8 out
of 9 in 5vp1
Go back to
Fluorine Binding Sites List in 5vp1
Fluorine binding site 8 out
of 9 in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 8 of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
C:F1003
b:30.1
occ:1.00
|
F29
|
C:9GA1003
|
0.0
|
30.1
|
1.0
|
C27
|
C:9GA1003
|
1.4
|
30.6
|
1.0
|
O26
|
C:9GA1003
|
2.3
|
29.7
|
1.0
|
F28
|
C:9GA1003
|
2.3
|
31.6
|
1.0
|
F30
|
C:9GA1003
|
2.3
|
31.7
|
1.0
|
CB
|
C:HIS773
|
3.0
|
29.4
|
1.0
|
CG2
|
C:THR805
|
3.2
|
22.3
|
1.0
|
CG
|
C:HIS773
|
3.3
|
30.4
|
1.0
|
C25
|
C:9GA1003
|
3.5
|
27.2
|
1.0
|
CD2
|
C:HIS773
|
3.7
|
31.6
|
1.0
|
CB
|
C:THR805
|
3.7
|
22.4
|
1.0
|
ND1
|
C:HIS773
|
4.0
|
30.6
|
1.0
|
CA
|
C:LEU770
|
4.0
|
27.7
|
1.0
|
CD1
|
C:LEU770
|
4.1
|
29.5
|
1.0
|
CD1
|
C:ILE870
|
4.2
|
27.1
|
1.0
|
C31
|
C:9GA1003
|
4.3
|
25.6
|
1.0
|
C24
|
C:9GA1003
|
4.4
|
27.3
|
1.0
|
O
|
C:ALA767
|
4.4
|
24.6
|
1.0
|
O
|
C:ASP769
|
4.5
|
26.4
|
1.0
|
N
|
C:LEU770
|
4.5
|
26.9
|
1.0
|
CA
|
C:HIS773
|
4.5
|
29.7
|
1.0
|
NE2
|
C:HIS773
|
4.5
|
32.4
|
1.0
|
OG1
|
C:THR805
|
4.5
|
22.9
|
1.0
|
CE1
|
C:HIS773
|
4.7
|
31.6
|
1.0
|
CB
|
C:LEU770
|
4.7
|
28.2
|
1.0
|
C
|
C:ASP769
|
4.7
|
26.8
|
1.0
|
O
|
C:LEU770
|
4.8
|
29.2
|
1.0
|
CA
|
C:THR805
|
4.9
|
21.8
|
1.0
|
O
|
C:HOH1137
|
4.9
|
28.2
|
1.0
|
C
|
C:LEU770
|
4.9
|
28.7
|
1.0
|
N
|
C:HIS773
|
4.9
|
29.2
|
1.0
|
O
|
C:THR768
|
4.9
|
24.6
|
1.0
|
O
|
C:HOH1131
|
5.0
|
26.4
|
1.0
|
|
Fluorine binding site 9 out
of 9 in 5vp1
Go back to
Fluorine Binding Sites List in 5vp1
Fluorine binding site 9 out
of 9 in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 9 of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
C:F1003
b:31.7
occ:1.00
|
F30
|
C:9GA1003
|
0.0
|
31.7
|
1.0
|
C27
|
C:9GA1003
|
1.4
|
30.6
|
1.0
|
F28
|
C:9GA1003
|
2.3
|
31.6
|
1.0
|
O26
|
C:9GA1003
|
2.3
|
29.7
|
1.0
|
F29
|
C:9GA1003
|
2.3
|
30.1
|
1.0
|
C25
|
C:9GA1003
|
2.8
|
27.2
|
1.0
|
C31
|
C:9GA1003
|
3.1
|
25.6
|
1.0
|
CB
|
C:THR805
|
3.2
|
22.4
|
1.0
|
CG2
|
C:THR805
|
3.4
|
22.3
|
1.0
|
CD1
|
C:LEU809
|
3.7
|
23.1
|
1.0
|
CA
|
C:THR805
|
3.8
|
21.8
|
1.0
|
C24
|
C:9GA1003
|
3.8
|
27.3
|
1.0
|
CG
|
C:LEU809
|
3.8
|
22.1
|
1.0
|
O
|
C:THR805
|
3.9
|
22.5
|
1.0
|
CD1
|
C:ILE870
|
4.0
|
27.1
|
1.0
|
CD2
|
C:LEU809
|
4.2
|
22.3
|
1.0
|
C32
|
C:9GA1003
|
4.2
|
24.9
|
1.0
|
C
|
C:THR805
|
4.3
|
22.2
|
1.0
|
OG1
|
C:THR805
|
4.4
|
22.9
|
1.0
|
CB
|
C:ASP808
|
4.6
|
21.8
|
1.0
|
C23
|
C:9GA1003
|
4.7
|
26.7
|
1.0
|
OD2
|
C:ASP808
|
4.8
|
24.6
|
1.0
|
O
|
C:THR768
|
4.9
|
24.6
|
1.0
|
C22
|
C:9GA1003
|
4.9
|
25.5
|
1.0
|
|
Reference:
S.Mikami,
M.Kawasaki,
S.Ikeda,
N.Negoro,
S.Nakamura,
I.Nomura,
T.Ashizawa,
H.Kokubo,
I.D.Hoffman,
H.Zou,
H.Oki,
N.Uchiyama,
Y.Hiura,
M.Miyamoto,
Y.Itou,
M.Nakashima,
H.Iwashita,
T.Taniguchi.
Discovery of A Novel Series of Pyrazolo[1,5-A]Pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different From N-((1S)-1-(3-Fluoro-4-(Trifluoromethoxy)Phenyl) -2-Methoxyethyl)-7-Methoxy-2-Oxo-2,3-Dihydropyrido[2, 3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), For the Treatment of Cognitive Disorders. Chem. Pharm. Bull. V. 65 1058 2017.
ISSN: ISSN 1347-5223
PubMed: 29093293
DOI: 10.1248/CPB.C17-00564
Page generated: Thu Aug 1 16:11:11 2024
|